| Entry |
|
|---|
| Name |
Alfuzosin hydrochloride (JAN/USAN);
Uroxatral (TN)
|
|---|
| Product |
|
|---|
| Generic |
ALFUZOSIN HYDROCHLORIDE (Aphena Pharma Solutions - Tennessee), ALFUZOSIN HYDROCHLORIDE (Apotex Corp.), ALFUZOSIN HYDROCHLORIDE (Aurobindo Pharma Limited), ALFUZOSIN HYDROCHLORIDE (Bryant Ranch Prepack), ALFUZOSIN HYDROCHLORIDE (Cipla USA), ALFUZOSIN HYDROCHLORIDE (Denton Pharma), ALFUZOSIN HYDROCHLORIDE (DirectRX), ALFUZOSIN HYDROCHLORIDE (Exelan Pharmaceuticals), ALFUZOSIN HYDROCHLORIDE (Rising Health), ALFUZOSIN HYDROCHLORIDE (Sun Pharmaceutical Industries), ALFUZOSIN HYDROCHLORIDE (Torrent Pharmaceuticals Limited), ALFUZOSIN HYDROCHLORIDE (Unichem Pharmaceuticals (USA)), ALFUZOSIN HYDROCHLORIDE (Wockhardt USA LLC.) |
|---|
| Formula |
C19H27N5O4. HCl
|
|---|
| Exact mass |
425.183
|
|---|
| Mol weight |
425.9097
|
|---|
| Structure |
   |
|---|
| Simcomp |
 |
|---|
| Class |
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
Metabolizing enzyme substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Product (DG00489): | D01692<US> |
|
|---|
| Efficacy |
Antidysuria, Antihypertensive, alpha1-Adrenergic receptor antagonist |
|---|
| Comment |
Prazosin derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04270 | Vascular smooth muscle contraction |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
G GENITO URINARY SYSTEM AND SEX HORMONES
G04 UROLOGICALS
G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
G04CA Alpha-adrenoreceptor antagonists
G04CA01 Alfuzosin
D01692 Alfuzosin hydrochloride (JAN/USAN) <US>
USP drug classification [BR:br08302]
Genitourinary Agents
Benign Prostatic Hypertrophy Agents
Alfuzosin
D01692 Alfuzosin hydrochloride (JAN/USAN)
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRA1A
D01692 Alfuzosin hydrochloride (JAN/USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01692
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01692
 |
|---|
| Other DBs |
|
|---|
| LinkDB |
 |
|---|
| KCF data |
ATOM 29
1 C8y C 21.4500 -13.4748
2 C8y C 21.4500 -12.0658
3 C8x C 22.6778 -14.1822
4 C8y C 20.2397 -14.1822
5 N5x N 20.2397 -11.3817
6 C8x C 22.6778 -11.3817
7 C8y C 23.8821 -13.4748
8 N5x N 19.0294 -13.4748
9 N1a N 20.2397 -15.5855
10 C8y C 19.0294 -12.0658
11 C8y C 23.8821 -12.0658
12 O2a O 25.1158 -14.1822
13 N1c N 17.8190 -11.3817
14 O2a O 25.1158 -11.3817
15 C1a C 26.3203 -13.4689
16 C1b C 16.5970 -12.0658
17 C1a C 26.3203 -12.0774
18 C1a C 17.8219 -9.9828
19 C1b C 15.3948 -11.3505
20 C1b C 14.1744 -12.0339
21 N1b N 12.9722 -11.3186
22 C5a C 11.7517 -12.0019
23 O5a O 11.7799 -13.4006
24 C1y C 10.5565 -11.3311
25 C1x C 10.1211 -10.0016
26 O2x O 9.4217 -12.1564
27 C1x C 8.2870 -11.3311
28 C1x C 8.7223 -10.0016
29 X Cl 29.5439 -12.6330
BOND 30
1 7 12 1
2 10 13 1
3 11 14 1
4 12 15 1
5 13 16 1
6 14 17 1
7 7 11 1
8 8 10 1
9 13 18 1
10 16 19 1
11 1 2 2
12 19 20 1
13 1 3 1
14 20 21 1
15 1 4 1
16 21 22 1
17 2 5 1
18 22 23 2
19 2 6 1
20 22 24 1
21 3 7 2
22 4 8 2
23 4 9 1
24 5 10 2
25 25 24 1
26 24 26 1
27 26 27 1
28 27 28 1
29 28 25 1
30 6 11 2
|
|---|
